EN DE
STOCK COMPARISON

Ever Supreme Bio Technology Co. vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Ever Supreme Bio Technology Co. (6712) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Ever Supreme Bio Technology Co. trades at TWD 157 versus a fair value of TWD 66.27 (-58%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Ever Supreme Bio Technology Co.
6712.TWO · TWD · Healthcare
-58%
upside to fair value
overvalued
PriceTWD 157
Fair ValueTWD 66.27
Quality85/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-44%
upside to fair value
overvalued
Price$496
Fair Value$279
Quality79/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Ever Supreme Bio Technology Co.Vertex Pharmaceuticals
Valuation
31.7×P/E (TTM)28.8×
13.70×P/S (TTM)10.06×
9.24×P/B6.59×
29.4×EV/EBITDA23.8×
PEG1.72×
2.2%Dividend yield
TWD 3.33Dividend per share
Profitability
46%Net margin36%
47%Operating margin38%
24%Return on equity24%
10%Return on assets12%
Growth
7%Revenue growth (YoY)8%
17.5%Avg. growth/yr (3Y)10.6%
70.5%Avg. growth/yr (5Y)14.2%
Balance & size
Debt / equity0.03×
$439MMarket cap$123B
healthyGrowth qualityhealthy

Vertex Pharmaceuticals leads: 4 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Ever Supreme Bio Technology Co.of which business quality 82 · market factors 48 Vertex Pharmaceuticalsof which business quality 77 · market factors 65
ProfitabilityMargins and returns on capital today
78
72
Quality GrowthAre margins and returns improving?
75
65
CashflowEarnings quality: real cash, not paper profit
88
79
Fin. StrengthBalance sheet, leverage, solvency risk
87
92
InvestmentDisciplined investing over empire-building
99
58
Low VolatilityCalm price path (market factor)
50
86
MomentumPrice trend over the last 3–12 months (market factor)
59
54
52W MomentumDistance to the 52-week high (market factor)
27
59
Net IssuanceBuybacks instead of dilution
61
82

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Ever Supreme Bio Technology Co.

DCF ModelsTWD 148
Earnings-BasedTWD 157
MultiplesTWD 56.51
Asset-BasedTWD 10.69
Growth DCFTWD 124
Economic ProfitTWD 61.92
Growth EarningsTWD 203

16 of 24 models see the stock below the current price.

Vertex Pharmaceuticals

DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692

18 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Ever Supreme Bio Technology Co.
Bear TWD 50.56Fair Value TWD 66.27Bull TWD 263
TWD 157 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$496 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Ever Supreme Bio Technology Co. · Healthcare

Quality score85 · Top 25%
Fair value upside-58% · below median

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-44% · below median

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Ever Supreme Bio Technology Co. trades at TWD 157 versus a fair value of TWD 66.27 (-58%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).

Ever Supreme Bio Technology Co. has the higher quality score (85/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.